Janssen aims to expand the label of delivery in the US and EU for its product, Darzalex, to include subcutaneous delivery through the use of Halozyme’s technology.
Genmab agrees deal with Janssen to develop a next-generation mAb product in oncology, which looks to build on the commercial success of the companies’ partnership on Darzalex.